JP2023520047A5 - - Google Patents

Info

Publication number
JP2023520047A5
JP2023520047A5 JP2022559873A JP2022559873A JP2023520047A5 JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5 JP 2022559873 A JP2022559873 A JP 2022559873A JP 2022559873 A JP2022559873 A JP 2022559873A JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cationic lipid
optionally substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559873A
Other languages
English (en)
Japanese (ja)
Other versions
JP7791103B2 (ja
JP2023520047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025128 external-priority patent/WO2021202694A1/en
Publication of JP2023520047A publication Critical patent/JP2023520047A/ja
Publication of JP2023520047A5 publication Critical patent/JP2023520047A5/ja
Priority to JP2025244099A priority Critical patent/JP2026048786A/ja
Application granted granted Critical
Publication of JP7791103B2 publication Critical patent/JP7791103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559873A 2020-04-01 2021-03-31 フェノール酸脂質系カチオン性脂質 Active JP7791103B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025244099A JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003698P 2020-04-01 2020-04-01
US63/003,698 2020-04-01
PCT/US2021/025128 WO2021202694A1 (en) 2020-04-01 2021-03-31 Phenolic acid lipid based cationic lipids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025244099A Division JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Publications (3)

Publication Number Publication Date
JP2023520047A JP2023520047A (ja) 2023-05-15
JP2023520047A5 true JP2023520047A5 (enExample) 2024-04-11
JP7791103B2 JP7791103B2 (ja) 2025-12-23

Family

ID=75625666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559873A Active JP7791103B2 (ja) 2020-04-01 2021-03-31 フェノール酸脂質系カチオン性脂質
JP2025244099A Pending JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025244099A Pending JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Country Status (4)

Country Link
EP (1) EP4126813A1 (enExample)
JP (2) JP7791103B2 (enExample)
CN (2) CN115667207B (enExample)
WO (1) WO2021202694A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313115A1 (en) 2021-03-25 2024-02-07 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
JP2024515668A (ja) * 2021-04-19 2024-04-10 トランスレイト バイオ, インコーポレイテッド Mrnaの送達のための改善された組成物
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
EP4637813A1 (en) 2022-12-20 2025-10-29 Sanofi Pasteur Rhinovirus mrna vaccine
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
TW202543585A (zh) 2024-03-08 2025-11-16 美商健臻公司 脂質奈米粒子
WO2026003373A1 (en) 2024-06-28 2026-01-02 Sanofi Phenolic acid lipid based cationic lipids
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1999052894A1 (en) * 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof
JP6557722B2 (ja) * 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
PL3386484T3 (pl) * 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
JP7488193B2 (ja) * 2018-05-24 2024-05-21 トランスレイト バイオ, インコーポレイテッド チオエステルカチオン性脂質
EP3849617A1 (en) * 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
CN110526885A (zh) * 2019-08-20 2019-12-03 上海英诺富成生物科技有限公司 麦考酚酸的前体药物及其制备方法

Similar Documents

Publication Publication Date Title
JP2023520047A5 (enExample)
RU2201224C2 (ru) Соединения, активные в новом сайте на рецептор-регулируемых кальциевых каналах и используемые для лечения неврологических расстройств и заболеваний
ES2163295T3 (es) Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.
JP2004514663A5 (enExample)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
RU2003120798A (ru) Новые производные n-(фенилсульфонил) глицина и их применение в терапии
RU99115746A (ru) Новые соединения с анальгезирующим действием
JP2002543202A5 (enExample)
RU2007111758A (ru) Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ
JP2023531709A5 (enExample)
CN102083773A (zh) {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法
JP2023538524A5 (enExample)
JPH0920659A5 (enExample)
JP2024545787A5 (enExample)
EP1261349A1 (en) Compounds with chelation affinity and selectivity for first transition series elements and their use
JP2023531495A5 (enExample)
JP2023542945A5 (enExample)
KR0130977B1 (ko) 항종양제로서 폴리아민 유도체
JP2024507414A5 (enExample)
JP2012506908A5 (enExample)
JP2004523478A5 (enExample)
RU2002118700A (ru) Замещенные производные норборниламина, способ их получения, их применение в качестве медикаментов или диагностических средств, а также содержащие их медикаменты
JP6017766B2 (ja) 新規な金属サレン錯体化合物の抗がん剤
IL97902A (en) Tetra-aza macrocycles processes for their preparation and their use in magnetic resonance imaging
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof